This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study toevaluate the safety and efficacy of investigational agents with or without pembrolizumaband/or chemotherapy, for the treatment of participants with second line (2L) esophagealsquamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 basedtreatment.
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study toevaluate the safety and efficacy of investigational agents with or without pembrolizumaband/or chemotherapy, for the treatment of participants with second line (2L) esophagealsquamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 basedtreatment.
